1. Home
  2. NUVL vs PDI Comparison

NUVL vs PDI Comparison

Compare NUVL & PDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$103.39

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo PIMCO Dynamic Income Fund

PDI

PIMCO Dynamic Income Fund

HOLD

Current Price

$18.22

Market Cap

7.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
PDI
Founded
2017
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.6B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
PDI
Price
$103.39
$18.22
Analyst Decision
Strong Buy
Analyst Count
15
0
Target Price
$135.00
N/A
AVG Volume (30 Days)
581.9K
1.5M
Earning Date
02-26-2026
01-01-0001
Dividend Yield
N/A
13.81%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$15.45
52 Week High
$113.02
$19.60

Technical Indicators

Market Signals
Indicator
NUVL
PDI
Relative Strength Index (RSI) 48.27 59.73
Support Level $100.19 $18.02
Resistance Level $107.51 $18.17
Average True Range (ATR) 4.89 0.08
MACD -0.41 0.01
Stochastic Oscillator 36.14 78.85

Price Performance

Historical Comparison
NUVL
PDI

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About PDI PIMCO Dynamic Income Fund

PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investment portfolio includes mortgage-backed securities, investment-grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.

Share on Social Networks: